Download PDF
Semin Respir Crit Care Med 2014; 35(02): 222-238
DOI: 10.1055/s-0034-1371542
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Rheumatoid Arthritis and Lung Disease: From Mechanisms to a Practical Approach

Fiona Lake
1   School of Medicine and Pharmacology, SCGH Unit, University of Western Australia, Nedlands, Western Australia, Australia
,
Susanna Proudman
2   Rheumatology Unit, Royal Adelaide Hospital, The University of Adelaide, Adelaide, South Australia, Australia
› Author Affiliations
Further Information

Publication History

Publication Date:
25 March 2014 (online)

   Permissions and Reprints

Abstract

Rheumatoid arthritis (RA) is a common chronic systemic autoimmune disease characterized by joint inflammation and, in a proportion of patients, extra-articular manifestations (EAM). Lung disease, either as an EAM of the disease, related to the drug therapy for RA, or related to comorbid conditions, is the second commonest cause of mortality. All areas of the lung including the pleura, airways, parenchyma, and vasculature may be involved, with interstitial and pleural disease and infection being the most common problems. High-resolution computed tomography of the chest forms the basis of investigation and when combined with clinical information and measures of physiology, a multidisciplinary team can frequently establish the diagnosis without the need for an invasive biopsy procedure. The most frequent patterns of interstitial lung disease (ILD) are usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), with some evidence for the prognosis being better than for the idiopathic equivalents. Risk factors depend on the type of disease but for ILD (mainly UIP and NSIP) include smoking, male gender, human leukocyte antigen haplotype, rheumatoid factor, and anticitrullinated protein antibodies (ACPAs). Citrullination of proteins in the lung, frequently thought to be incited by smoking, and the subsequent development of ACPA appear to play an important role in the development of lung and possibly joint disease. The biologic and nonbiological disease modifying antirheumatic drugs (DMARDs) have had a substantial impact on morbidity and mortality from RA, and although there multiple reports of drug-related lung toxicity and possible exacerbation of underlying ILD, overall these reactions are rare and should only preclude the use of DMARDs in a minority of patients. Common scenarios facing pulmonologists and rheumatologists are addressed using the current best evidence; these include screening the new patient; monitoring and choosing RA treatment in the presence of subclinical disease; treating deteriorating ILD; and establishing a diagnosis in a patient with an acute respiratory presentation.

Keywords

rheumatoid arthritis - lung - interstitial - drug induced - anticitrullinated protein antibodies - biologic disease modifying antirheumatic drugs - prognosis
 

  • References

  • 1 van Nies JA, Krabben A, Schoones JW, Huizinga TW, Kloppenburg M, van der Helm-van Mil AH. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis 2013; 0: 1-10
    PubMedGoogle Scholar
  • 2 Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol 2013; 25 (3) 360-366
    CrossrefPubMedGoogle Scholar
  • 3 Brown KK. Rheumatoid lung disease. Proc Am Thorac Soc 2007; 4 (5) 443-448
    CrossrefPubMedGoogle Scholar
  • 4 O'Dwyer DN, Armstrong ME, Cooke G, Dodd JD, Veale DJ, Donnelly SC. Rheumatoid arthritis (RA) associated interstitial lung disease (ILD). Eur J Intern Med 2013; 24 (7) 597-603
    CrossrefPubMedGoogle Scholar
  • 5 Kelly C, Hamilton J. What kills patients with rheumatoid arthritis?. Rheumatology (Oxford) 2007; 46 (2) 183-184
    PubMedGoogle Scholar
  • 6 Young A, Koduri G, Batley M , et al; Early Rheumatoid Arthritis Study (ERAS) group. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 2007; 46 (2) 350-357
    PubMedGoogle Scholar
  • 7 Bongartz T, Nannini C, Medina-Velasquez YF , et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 2010; 62 (6) 1583-1591
    CrossrefPubMedGoogle Scholar
  • 8 Gizinski AM, Mascolo M, Loucks JL , et al. Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol 2009; 28 (5) 611-613
    CrossrefPubMedGoogle Scholar
  • 9 Chen J, Shi Y, Wang X, Huang H, Ascherman D. Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease. Clin Dev Immunol 2013; 2013: 406927
    PubMedGoogle Scholar
  • 10 Deane KD, Nicolls MR. Developing better biomarkers for connective tissue disease-associated interstitial lung disease: citrullinated hsp90 autoantibodies in rheumatoid arthritis. Arthritis Rheum 2013; 65 (4) 864-868
    CrossrefPubMedGoogle Scholar
  • 11 Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review. Semin Arthritis Rheum 2013; pii: S0049-0172(13)00201-1
    PubMedGoogle Scholar
  • 12 Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med 2012; 185 (11) 1147-1153
    CrossrefPubMedGoogle Scholar
  • 13 Picchianti Diamanti A, Germano V, Bizzi E, Laganà B, Migliore A. Interstitial lung disease in rheumatoid arthritis in the era of biologics. Pulm Med 2011; 2011: 931342
    PubMedGoogle Scholar
  • 14 Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology (Oxford) 2012; 51 (Suppl. 06) vi37-vi43
    CrossrefPubMedGoogle Scholar
  • 15 Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford) 2012; 51 (Suppl. 06) vi28-vi36
    PubMedGoogle Scholar
  • 16 Atzeni F, Boiardi L, Sallì S, Benucci M, Sarzi-Puttini P. Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis. Expert Rev Clin Immunol 2013; 9 (7) 649-657
    CrossrefPubMedGoogle Scholar
  • 17 van Dartel SAA, Fransen J, Kievit W , et al. Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology (Oxford) 2013; 52 (6) 1052-1057
    CrossrefPubMedGoogle Scholar
  • 18 Marigliano B, Soriano A, Margiotta D, Vadacca M, Afeltra A. Lung involvement in connective tissue diseases: a comprehensive review and a focus on rheumatoid arthritis. Autoimmun Rev 2013; 12 (11) 1076-1084
    CrossrefPubMedGoogle Scholar
  • 19 Khurana R, Wolf R, Berney S, Caldito G, Hayat S, Berney SM. Risk of development of lung cancer is increased in patients with rheumatoid arthritis: a large case control study in US veterans. J Rheumatol 2008; 35 (9) 1704-1708
    PubMedGoogle Scholar
  • 20 Bruzzese V, Hassan C, Ridola L, Zullo A. Rheumatoid arthritis and cardiovascular risk: between lights and shadows. Curr Rheumatol Rev 2013; 9 (2) 100-104
    CrossrefPubMedGoogle Scholar
  • 21 Corcoran JP, Ahmad M, Mukherjee R, Redmond KC. Pleuro-Pulmonary Complications of Rheumatoid Arthritis. Respir Care 2013; (e-pub ahead of print). doi:10.4187/respcare.02597
    PubMedGoogle Scholar
  • 22 Balbir-Gurman A, Yigla M, Nahir AM, Braun-Moscovici Y. Rheumatoid pleural effusion. Semin Arthritis Rheum 2006; 35 (6) 368-378
    CrossrefPubMedGoogle Scholar
  • 23 Perez T, Remy-Jardin M, Cortet B. Airways involvement in rheumatoid arthritis: clinical, functional, and HRCT findings. Am J Respir Crit Care Med 1998; 157 (5 Pt 1) 1658-1665
    CrossrefPubMedGoogle Scholar
  • 24 Shahane A. Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis. Rheumatol Int 2013; 33 (7) 1655-1667
    CrossrefPubMedGoogle Scholar
  • 25 Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M, Xaubet A, Bosch X ; BIOGEAS Study Group. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med 2011; 124 (5) 386-394
    CrossrefPubMedGoogle Scholar
  • 26 Hadjinicolaou AV, Nisar MK, Bhagat S, Parfrey H, Chilvers ER, Ostör AJ. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases—a systematic literature review. Rheumatology (Oxford) 2011; 50 (12) 2297-2305
    CrossrefPubMedGoogle Scholar
  • 27 Holmqvist ME, Neovius M, Eriksson J , et al. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA 2012; 308 (13) 1350-1356
    CrossrefPubMedGoogle Scholar
  • 28 Kim SC, Schneeweiss S, Liu J, Solomon DH. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013; 65 (10) 1600-1607
    PubMedGoogle Scholar
  • 29 Mercer LK, Davies R, Galloway JB , et al; British Society for Rheumatology Biologics Register (BSRBR) Control Centre Consortium. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford) 2013; 52 (1) 91-98
    CrossrefPubMedGoogle Scholar
  • 30 Rueth N, Andrade R, Groth S, D'Cunha J, Maddaus M. Pleuropulmonary complications of rheumatoid arthritis: a thoracic surgeon's challenge. Ann Thorac Surg 2009; 88 (3) e20-e21
    CrossrefPubMedGoogle Scholar
  • 31 Avnon LS, Abu-Shakra M, Flusser D, Heimer D, Sion-Vardy N. Pleural effusion associated with rheumatoid arthritis: what cell predominance to anticipate?. Rheumatol Int 2007; 27 (10) 919-925
    CrossrefPubMedGoogle Scholar
  • 32 Chapman PT, O'Donnell JL, Moller PW. Rheumatoid pleural effusion: response to intrapleural corticosteroid. J Rheumatol 1992; 19 (3) 478-480
    PubMedGoogle Scholar
  • 33 Nishida C, Yatera K, Kunimoto M , et al. [A case of rheumatoid arthritis with pneumothorax due to subpleural pulmonary rheumatoid nodules]. Nihon Kokyuki Gakkai Zasshi 2008; 46 (11) 934-939
    PubMedGoogle Scholar
  • 34 Ahmed R, Ahmed U, Syed I. Pneumothorax necessitans in a patient with trapped lung and rheumatoid arthritis. BMJ Case Rep 2013; 2013 ;pii: bcr2013009263. doi: 10.1136/bcr-2013-009263
    PubMedGoogle Scholar
  • 35 Nannini C, Medina-Velasquez YF, Achenbach SJ , et al. Incidence and mortality of obstructive lung disease in rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken) 2013; 65 (8) 1243-1250
    PubMedGoogle Scholar
  • 36 Greco A, Fusconi M, Macri GF , et al. Cricoarytenoid joint involvement in rheumatoid arthritis: radiologic evaluation. Am J Otolaryngol 2012; 33 (6) 753-755
    CrossrefPubMedGoogle Scholar
  • 37 Mori S, Koga Y, Sugimoto M. Small airway obstruction in patients with rheumatoid arthritis. Mod Rheumatol 2011; 21 (2) 164-173
    CrossrefPubMedGoogle Scholar
  • 38 Fuld JP, Johnson MK, Cotton MM , et al. A longitudinal study of lung function in nonsmoking patients with rheumatoid arthritis. Chest 2003; 124 (4) 1224-1231
    CrossrefPubMedGoogle Scholar
  • 39 Ayhan-Ardic FF, Oken O, Yorgancioglu ZR, Ustun N, Gokharman FD. Pulmonary involvement in lifelong non-smoking patients with rheumatoid arthritis and ankylosing spondylitis without respiratory symptoms. Clin Rheumatol 2006; 25 (2) 213-218
    CrossrefPubMedGoogle Scholar
  • 40 Hayakawa H, Sato A, Imokawa S, Toyoshima M, Chida K, Iwata M. Bronchiolar disease in rheumatoid arthritis. Am J Respir Crit Care Med 1996; 154 (5) 1531-1536
    CrossrefPubMedGoogle Scholar
  • 41 Devouassoux G, Cottin V, Lioté H , et al; Groupe d'Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires (GERM”O”P). Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis. Eur Respir J 2009; 33 (5) 1053-1061
    CrossrefPubMedGoogle Scholar
  • 42 Schwarz MI, Lynch DA, Tuder R. Bronchiolitis obliterans: the lone manifestation of rheumatoid arthritis?. Eur Respir J 1994; 7 (4) 817-820
    CrossrefPubMedGoogle Scholar
  • 43 Wilczynska MM, Condliffe AM, McKeon DJ. Coexistence of bronchiectasis and rheumatoid arthritis: revisited. Respir Care 2013; 58 (4) 694-701
    CrossrefPubMedGoogle Scholar
  • 44 Gabbay E, Tarala R, Will R , et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 1997; 156 (2 Pt 1) 528-535
    CrossrefPubMedGoogle Scholar
  • 45 Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 2001; 56 (8) 622-627
    CrossrefPubMedGoogle Scholar
  • 46 Youssef AA, Machaly SA, El-Dosoky ME, El-Maghraby NM. Respiratory symptoms in rheumatoid arthritis: relation to pulmonary abnormalities detected by high-resolution CT and pulmonary functional testing. Rheumatol Int 2012; 32 (7) 1985-1995
    CrossrefPubMedGoogle Scholar
  • 47 Wilsher M, Voight L, Milne D , et al. Prevalence of airway and parenchymal abnormalities in newly diagnosed rheumatoid arthritis. Respir Med 2012; 106 (10) 1441-1446
    CrossrefPubMedGoogle Scholar
  • 48 Schreiber J, Koschel D, Kekow J, Waldburg N, Goette A, Merget R. Rheumatoid pneumoconiosis (Caplan's syndrome). Eur J Intern Med 2010; 21 (3) 168-172
    CrossrefPubMedGoogle Scholar
  • 49 Sharma S, Vaccharajani A, Mandke J. Severe pulmonary hypertension in rheumatoid arthritis. Int J Cardiol 1990; 26 (2) 220-222
    CrossrefPubMedGoogle Scholar
  • 50 Castro GW, Appenzeller S, Bertolo MB, Costallat LT. Isolated pulmonary hypertension secondary to rheumatoid arthritis. Clin Rheumatol 2006; 25 (6) 901-903
    CrossrefPubMedGoogle Scholar
  • 51 Udayakumar N, Venkatesan S, Rajendiran C. Pulmonary hypertension in rheumatoid arthritis—relation with the duration of the disease. Int J Cardiol 2008; 127 (3) 410-412
    CrossrefPubMedGoogle Scholar
  • 52 Blumentals WA, Arreglado A, Napalkov P, Toovey S. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord 2012; 13: 158-168
    CrossrefPubMedGoogle Scholar
  • 53 Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 2013; 52 (1) 53-61
    CrossrefPubMedGoogle Scholar
  • 54 Coyne P, Hamilton J, Heycock C, Saravanan V, Coulson E, Kelly CA. Acute lower respiratory tract infections in patients with rheumatoid arthritis. J Rheumatol 2007; 34 (9) 1832-1836
    PubMedGoogle Scholar
  • 55 Wells AU, Ward S. Pulmonary function tests in idiopathic pulmonary fibrosis. In: Meyer KC, Nathan SD, , eds. Idiopathic Pulmonary Fibrosis: A Comprehensive Clinical Guide, Respiratory Medicine. Vol. 9. Springer Science + Business Media: New York; 2014
    CrossrefGoogle Scholar
  • 56 Koduri G, Norton S, Young A , et al; ERAS (Early Rheumatoid Arthritis Study). Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford) 2010; 49 (8) 1483-1489
    CrossrefPubMedGoogle Scholar
  • 57 Weyand CM, Schmidt D, Wagner U, Goronzy JJ. The influence of sex on the phenotype of rheumatoid arthritis. Arthritis Rheum 1998; 41 (5) 817-822
    CrossrefPubMedGoogle Scholar
  • 58 Saag KG, Kolluri S, Koehnke RK , et al. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum 1996; 39 (10) 1711-1719
    CrossrefPubMedGoogle Scholar
  • 59 Gochuico BR, Avila NA, Chow CK , et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008; 168 (2) 159-166
    CrossrefPubMedGoogle Scholar
  • 60 Biederer J, Schnabel A, Muhle C, Gross WL, Heller M, Reuter M. Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis. Eur Radiol 2004; 14 (2) 272-280
    CrossrefPubMedGoogle Scholar
  • 61 Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med 2012; 106 (11) 1591-1599
    CrossrefPubMedGoogle Scholar
  • 62 Klareskog L, Stolt P, Lundberg K , et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54 (1) 38-46
    CrossrefPubMedGoogle Scholar
  • 63 Bongartz T, Cantaert T, Atkins SR , et al. Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford) 2007; 46 (1) 70-75
    CrossrefPubMedGoogle Scholar
  • 64 Harlow L, Rosas IO, Gochuico BR , et al. Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheum 2013; 65 (4) 869-879
    CrossrefPubMedGoogle Scholar
  • 65 Nishimura K, Sugiyama D, Kogata Y , et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146 (11) 797-808
    CrossrefPubMedGoogle Scholar
  • 66 Fischer A, Solomon JJ, du Bois RM , et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med 2012; 106 (7) 1040-1047
    CrossrefPubMedGoogle Scholar
  • 67 Giles JT, Danoff SK, Sokolove J , et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis 2013; (e-pub ahead of print). doi:10.1136/annrheumdis-2012-203160
    PubMedGoogle Scholar
  • 68 Willis VC, Demoruelle MK, Derber LA , et al. Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. Arthritis Rheum 2013; 65 (10) 2545-2554
    PubMedGoogle Scholar
  • 69 Turesson C, Jacobsson LT, Sturfelt G, Matteson EL, Mathsson L, Rönnelid J. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 2007; 66 (1) 59-64
    PubMedGoogle Scholar
  • 70 Suzuki A, Ohosone Y, Obana M , et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol 1994; 21 (1) 33-36
    PubMedGoogle Scholar
  • 71 Sihvonen S, Korpela M, Laippala P, Mustonen J, Pasternack A. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol 2004; 33 (4) 221-227
    CrossrefPubMedGoogle Scholar
  • 72 Travis WD, Costabel U, Hansell DM , et al; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188 (6) 733-748
    CrossrefPubMedGoogle Scholar
  • 73 Flaherty KR, Colby TV, Travis WD , et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med 2003; 167 (10) 1410-1415
    CrossrefPubMedGoogle Scholar
  • 74 Vij R, Noth I, Strek ME. Autoimmune-featured interstitial lung disease: a distinct entity. Chest 2011; 140 (5) 1292-1299
    CrossrefPubMedGoogle Scholar
  • 75 Larsen BT, Colby TV. Update for pathologists on idiopathic interstitial pneumonias. Arch Pathol Lab Med 2012; 136 (10) 1234-1241
    CrossrefPubMedGoogle Scholar
  • 76 Wells AU. The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF)—practical implications. Respir Res 2013; 14 (Suppl. 01) S2
    CrossrefPubMedGoogle Scholar
  • 77 Castelino FV, Goldberg H, Dellaripa PF. The impact of rheumatological evaluation in the management of patients with interstitial lung disease. Rheumatology (Oxford) 2011; 50 (3) 489-493
    CrossrefPubMedGoogle Scholar
  • 78 Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 2013; 143 (3) 814-824
    CrossrefPubMedGoogle Scholar
  • 79 Cottin V, Cordier JF. Subclinical interstitial lung disease: no place for crackles?. Am J Respir Crit Care Med 2012; 186 (3) 289 , author reply 289–290
    PubMedGoogle Scholar
  • 80 Lee HK, Kim DS, Yoo B , et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005; 127 (6) 2019-2027
    CrossrefPubMedGoogle Scholar
  • 81 Yoshinouchi T, Ohtsuki Y, Fujita J , et al. Nonspecific interstitial pneumonia pattern as pulmonary involvement of rheumatoid arthritis. Rheumatol Int 2005; 26 (2) 121-125
    CrossrefPubMedGoogle Scholar
  • 82 Rees JH, Woodhead MA, Sheppard MN, du Bois RM. Rheumatoid arthritis and cryptogenic organising pneumonitis. Respir Med 1991; 85 (3) 243-246
    CrossrefPubMedGoogle Scholar
  • 83 Cohen AJ, King Jr TE, Downey GP. Rapidly progressive bronchiolitis obliterans with organizing pneumonia. Am J Respir Crit Care Med 1994; 149 (6) 1670-1675
    CrossrefPubMedGoogle Scholar
  • 84 Ippolito JA, Palmer L, Spector S, Kane PB, Gorevic PD. Bronchiolitis obliterans organizing pneumonia and rheumatoid arthritis. Semin Arthritis Rheum 1993; 23 (1) 70-78
    CrossrefPubMedGoogle Scholar
  • 85 Rajasekaran A, Shovlin D, Saravanan V, Lord P, Kelly C. Interstitial lung disease in patients with rheumatoid arthritis: comparison with cryptogenic fibrosing alveolitis over 5 years. J Rheumatol 2006; 33 (7) 1250-1253
    PubMedGoogle Scholar
  • 86 Tansey D, Wells AU, Colby TV , et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004; 44 (6) 585-596
    CrossrefPubMedGoogle Scholar
  • 87 Hamblin MJ, Horton MR. Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemma. Pulm Med 2011; 2011: 872120
    PubMedGoogle Scholar
  • 88 de Lauretis A, Veeraraghavan S, Renzoni E. Review series: aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?. Chron Respir Dis 2011; 8 (1) 53-82
    CrossrefPubMedGoogle Scholar
  • 89 Mori S, Cho I, Koga Y, Sugimoto M. Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. J Rheumatol 2008; 35 (8) 1513-1521
    PubMedGoogle Scholar
  • 90 Kim EJ, Collard HR, King Jr TE. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 2009; 136 (5) 1397-1405
    CrossrefPubMedGoogle Scholar
  • 91 Wells AU. Managing diagnostic procedures in idiopathic pulmonary fibrosis. Eur Respir Rev 2013; 22 (128) 158-162
    CrossrefPubMedGoogle Scholar
  • 92 Schmidt SL, Sundaram B, Flaherty KR. Diagnosing fibrotic lung disease: when is high-resolution computed tomography sufficient to make a diagnosis of idiopathic pulmonary fibrosis?. Respirology 2009; 14 (7) 934-939
    CrossrefPubMedGoogle Scholar
  • 93 Tanaka N, Kim JS, Newell JD , et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology 2004; 232 (1) 81-91
    CrossrefPubMedGoogle Scholar
  • 94 Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet 2012; 380 (9842) 689-698
    CrossrefPubMedGoogle Scholar
  • 95 Goh NS, Desai SR, Veeraraghavan S , et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177 (11) 1248-1254
    CrossrefPubMedGoogle Scholar
  • 96 Walsh SLF, Sverzellati N, Devaraj A, Keir GJ, Wells AU, Hansell DM. Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax 2013;
    PubMedGoogle Scholar
  • 97 Song J-W, Lee H-K, Lee Et Al CK. Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30 (2) 103-112
    PubMedGoogle Scholar
  • 98 Hakala M. Poor prognosis in patients with rheumatoid arthritis hospitalized for interstitial lung fibrosis. Chest 1988; 93 (1) 114-118
    CrossrefPubMedGoogle Scholar
  • 99 Solomon JJ, Ryu JH, Tazelaar HD , et al. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respir Med 2013; 107 (8) 1247-1252
    CrossrefPubMedGoogle Scholar
  • 100 Tsuchiya Y, Takayanagi N, Sugiura H , et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J 2011; 37 (6) 1411-1417
    CrossrefPubMedGoogle Scholar
  • 101 Hubbard R, Venn A. The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology (Oxford) 2002; 41 (6) 676-679
    CrossrefPubMedGoogle Scholar
  • 102 Park JH, Kim DS, Park IN , et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175 (7) 705-711
    CrossrefPubMedGoogle Scholar
  • 103 Ryerson CJ, Urbania TH, Richeldi L , et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J 2013; 42 (3) 750-757
    CrossrefPubMedGoogle Scholar
  • 104 Cottin V. Pragmatic prognostic approach of rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010; 35 (6) 1206-1208
    CrossrefPubMedGoogle Scholar
  • 105 Vassallo R, Matteson E, Thomas Jr CF. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest 2002; 122 (3) 1093-1096
    CrossrefPubMedGoogle Scholar
  • 106 Chang HK, Park W, Ryu DS. Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report. J Korean Med Sci 2002; 17 (2) 270-273
    CrossrefPubMedGoogle Scholar
  • 107 Kobayashi A, Okamoto H. Treatment of interstitial lung diseases associated with connective tissue diseases. Expert Rev Clin Pharmacol 2012; 5 (2) 219-227
    CrossrefPubMedGoogle Scholar
  • 108 Puttick MP, Klinkhoff AV, Chalmers A, Ostrow DN. Treatment of progressive rheumatoid interstitial lung disease with cyclosporine. J Rheumatol 1995; 22 (11) 2163-2165
    PubMedGoogle Scholar
  • 109 Danoff SK, Schonhoft EH. Role of support measures and palliative care. Curr Opin Pulm Med 2013; 19 (5) 480-484
    CrossrefPubMedGoogle Scholar
  • 110 Gilbert CR, Smith CM. Advanced lung disease: quality of life and role of palliative care. Mt Sinai J Med 2009; 76 (1) 63-70
    CrossrefPubMedGoogle Scholar
  • 111 Meyer KC. Management of interstitial lung disease in elderly patients. Curr Opin Pulm Med 2012; 18 (5) 483-492
    CrossrefPubMedGoogle Scholar
  • 112 Kim SH, Yoo WH. Recurrent pneumothorax associated with pulmonary nodules after leflunomide therapy in rheumatoid arthritis: a case report and review of the literature. Rheumatol Int 2011; 31 (7) 919-922
    CrossrefPubMedGoogle Scholar
  • 113 Camus P. The Drug-Induced Respiratory Disease Web site. Available at: www.pneumotox.com . Accessed October 21, 2013
    PubMedGoogle Scholar
  • 114 Goodwin SD, Glenny RW. Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia. Review of the literature and Food and Drug Administration Adverse Drug Reaction reports. Arch Intern Med 1992; 152 (7) 1521-1524
    CrossrefPubMedGoogle Scholar
  • 115 Vogts N, Young S. Pulmonary infiltrates with eosinophilia syndrome in ibuprofen overdose. N Z Med J 2012; 125 (1360) 74-75
    PubMedGoogle Scholar
  • 116 Ethgen O, de Lemos Esteves F, Bruyere O, Reginster JY. What do we know about the safety of corticosteroids in rheumatoid arthritis?. Curr Med Res Opin 2013; 29 (9) 1147-1160
    CrossrefPubMedGoogle Scholar
  • 117 Dixon WG, Suissa S, Hudson M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther 2011; 13 (4) R139
    CrossrefPubMedGoogle Scholar
  • 118 Dixon WG, Abrahamowicz M, Beauchamp ME , et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012; 71 (7) 1128-1133
    CrossrefPubMedGoogle Scholar
  • 119 Chikura B, Sathi N, Lane S, Dawson JK. Variation of immunological response in methotrexate-induced pneumonitis. Rheumatology (Oxford) 2008; 47 (11) 1647-1650
    CrossrefPubMedGoogle Scholar
  • 120 Collins K, Aspey H, Todd A, Saravanan V, Rynne M, Kelly C. Methotrexate pneumonitis precipitated by switching from oral to parenteral administration. Rheumatology (Oxford) 2008; 47 (1) 109-110
    CrossrefPubMedGoogle Scholar
  • 121 Kremer JM, Alarcón GS, Weinblatt ME , et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997; 40 (10) 1829-1837
    CrossrefPubMedGoogle Scholar
  • 122 Alarcón GS, Kremer JM, Macaluso M , et al; Methotrexate-Lung Study Group. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Ann Intern Med 1997; 127 (5) 356-364
    CrossrefPubMedGoogle Scholar
  • 123 Kramer N, Chuzhin Y, Kaufman LD, Ritter JM, Rosenstein ED. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum 2002; 47 (6) 670-671
    CrossrefPubMedGoogle Scholar
  • 124 Dayton CS, Schwartz DA, Sprince NL , et al. Low-dose methotrexate may cause air trapping in patients with rheumatoid arthritis. Am J Respir Crit Care Med 1995; 151 (4) 1189-1193
    PubMedGoogle Scholar
  • 125 Dawson JK, Graham DR, Desmond J, Fewins HE, Lynch MP. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford) 2002; 41 (3) 262-267
    CrossrefPubMedGoogle Scholar
  • 126 Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006; 54 (5) 1435-1439
    CrossrefPubMedGoogle Scholar
  • 127 Chikura B, Lane S, Dawson JK. Clinical expression of leflunomide-induced pneumonitis. Rheumatology (Oxford) 2009; 48 (9) 1065-1068
    CrossrefPubMedGoogle Scholar
  • 128 Sawada T, Inokuma S, Sato T , et al; Study Committee for Leflunomide-induced Lung Injury, Japan College of Rheumatology. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 2009; 48 (9) 1069-1072
    CrossrefPubMedGoogle Scholar
  • 129 Tomioka R, King Jr TE. Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease. Am J Respir Crit Care Med 1997; 155 (3) 1011-1020
    CrossrefPubMedGoogle Scholar
  • 130 van de Laar MA, Westermann CJ, Wagenaar SS, Dinant HJ. Beneficial effect of intravenous cyclophosphamide and oral prednisone on D-penicillamine-associated bronchiolitis obliterans. Arthritis Rheum 1985; 28 (1) 93-97
    CrossrefPubMedGoogle Scholar
  • 131 Furst DE, Keystone EC, So AK , et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2013; 72 (Suppl. 02) ii2-ii34
    CrossrefPubMedGoogle Scholar
  • 132 Mariette X, Gottenberg JE, Ravaud P, Combe B. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 2011; 50 (1) 222-229
    CrossrefPubMedGoogle Scholar
  • 133 Koike T, Harigai M, Inokuma S , et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 2009; 36 (5) 898-906
    CrossrefPubMedGoogle Scholar
  • 134 Peno-Green L, Lluberas G, Kingsley T, Brantley S. Lung injury linked to etanercept therapy. Chest 2002; 122 (5) 1858-1860
    CrossrefPubMedGoogle Scholar
  • 135 Ognenovski VM, Ojo TC, Fox DA. Etanercept-associated pulmonary granulomatous inflammation in patients with rheumatoid arthritis. J Rheumatol 2008; 35 (11) 2279-2282
    PubMedGoogle Scholar
  • 136 Toussirot E, Berthelot JM, Pertuiset E , et al. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series. J Rheumatol 2009; 36 (11) 2421-2427
    CrossrefPubMedGoogle Scholar
  • 137 Ostör AJ, Chilvers ER, Somerville MF , et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol 2006; 33 (3) 622-628
    PubMedGoogle Scholar
  • 138 Tai TL, O'Rourke KP, McWeeney M, Burke CM, Sheehan K, Barry M. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology (Oxford) 2002; 41 (8) 951-952
    CrossrefPubMedGoogle Scholar
  • 139 Huggett MT, Armstrong R. Adalimumab-associated pulmonary fibrosis. Rheumatology (Oxford) 2006; 45 (10) 1312-1313
    CrossrefPubMedGoogle Scholar
  • 140 Dixon WG, Hyrich KL, Watson KD , et al; B S R B R Control Centre Consortium; BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69 (3) 522-528
    CrossrefPubMedGoogle Scholar
  • 141 Fleischmann RM, Tesser J, Schiff MH , et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65 (8) 1006-1012
    CrossrefPubMedGoogle Scholar
  • 142 Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009; 68 (1) 25-32
    PubMedGoogle Scholar
  • 143 Soubrier M, Jeannin G, Kemeny JL , et al. Organizing pneumonia after rituximab therapy: Two cases. Joint Bone Spine 2008; 75 (3) 362-365
    CrossrefPubMedGoogle Scholar
  • 144 Matteson EL, Bongartz T, Ryu JH , et al. Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. Open J Rheumatol Autoimmun Dis 2012; 2 (3) 53-58
    PubMedGoogle Scholar
  • 145 Teichmann LL, Woenckhaus M, Vogel C, Salzberger B, Schölmerich J, Fleck M. Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology (Oxford) 2008; 47 (8) 1256-1257
    CrossrefPubMedGoogle Scholar
  • 146 Lee YH, Bae SC, Song GG. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int 2011; 31 (11) 1493-1499
    CrossrefPubMedGoogle Scholar
  • 147 Strangfeld A, Eveslage M, Schneider M , et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?. Ann Rheum Dis 2011; 70 (11) 1914-1920
    CrossrefPubMedGoogle Scholar
  • 148 Gottenberg JE, Ravaud P, Bardin T , et al; AutoImmunity and Rituximab registry and French Society of Rheumatology. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010; 62 (9) 2625-2632
    CrossrefPubMedGoogle Scholar
  • 149 Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis 2007; 66 (3) 308-312
    CrossrefPubMedGoogle Scholar
  • 150 McLean-Tooke A, Aldridge C, Waugh S, Spickett GP, Kay L. Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?. Rheumatology (Oxford) 2009; 48 (8) 867-871
    CrossrefPubMedGoogle Scholar
  • 151 Housden MM, Bell G, Heycock CR, Hamilton J, Saravanan V, Kelly CA. How to reduce morbidity and mortality from chest infections in rheumatoid arthritis. Clin Med 2010; 10 (4) 326-329
    CrossrefPubMedGoogle Scholar
  • 152 Kameda H, Tokuda H, Sakai F , et al. Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study. Intern Med 2011; 50 (4) 305-313
    CrossrefPubMedGoogle Scholar
  • 153 Singh JA, Furst DE, Bharat A , et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care res 2012; 64: 625-639
    CrossrefPubMedGoogle Scholar
  • 154 Mori S, Tokuda H, Sakai F , et al; NTM-BIORA (NTM infection in Biologic-treated RA patients) Study Investigators. Radiological features and therapeutic responses of pulmonary nontuberculous mycobacterial disease in rheumatoid arthritis patients receiving biological agents: a retrospective multicenter study in Japan. Mod Rheumatol 2012; 22 (5) 727-737
    CrossrefPubMedGoogle Scholar
  • 155 Mori S, Sugimoto M. Is continuation of anti-tumor necrosis factor-α therapy a safe option for patients who have developed pulmonary mycobacterial infection?: Case presentation and literature review. Clin Rheumatol 2012; 31 (2) 203-210
    CrossrefPubMedGoogle Scholar
  • 156 Yamakawa H, Takayanagi N, Miyahara Y , et al. Prognostic factors and radiographic outcomes of nontuberculous mycobacterial lung disease in rheumatoid arthritis. J Rheumatol 2013; 40 (8) 1307-1315
    CrossrefPubMedGoogle Scholar
  • 157 Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008; 59 (8) 1074-1081
    CrossrefPubMedGoogle Scholar
  • 158 Puéchal X, Fajac I, Bienvenu T , et al. Increased frequency of cystic fibrosis deltaF508 mutation in bronchiectasis associated with rheumatoid arthritis. Eur Respir J 1999; 13 (6) 1281-1287
    CrossrefPubMedGoogle Scholar
  • 159 Puéchal X, Bienvenu T, Génin E , et al. Mutations of the cystic fibrosis gene in patients with bronchiectasis associated with rheumatoid arthritis. Ann Rheum Dis 2011; 70 (4) 653-659
    CrossrefPubMedGoogle Scholar
  • 160 Mikuls TR. Rheumatoid arthritis incidence: what goes down must go up?. Arthritis Rheum 2010; 62 (6) 1565-1567
    CrossrefPubMedGoogle Scholar
  • 161 Gabriel SE, Crowson CS, Kremers HM , et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003; 48 (1) 54-58
    CrossrefPubMedGoogle Scholar
  • 162 Glace B, Gottenberg JE, Mariette X , et al. Efficacy of rituximab in the treatment of pulmonary rheumatoid nodules: findings in 10 patients from the French AutoImmunity and Rituximab/Rheumatoid Arthritis registry (AIR/PR registry). Ann Rheum Dis 2012; 71 (8) 1429-1431
    CrossrefPubMedGoogle Scholar
  • 163 Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C , et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011; 41 (2) 256-264
    CrossrefPubMedGoogle Scholar
  • 164 Scherak O, Popp W, Kolarz G, Wottawa A, Ritschka L, Braun O. Bronchoalveolar lavage and lung biopsy in rheumatoid arthritis. In vivo effects of disease modifying antirheumatic drugs. J Rheumatol 1993; 20 (6) 944-949
    PubMedGoogle Scholar
  • 165 Dixon WG, Hyrich KL, Watson KD, Lunt M, Symmons DP ; BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010; 69 (6) 1086-1091
    CrossrefPubMedGoogle Scholar
  • 166 Baughman RP, Meyer KC, Nathanson I , et al. Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 142 (5) e1S-e111S
    CrossrefPubMedGoogle Scholar